18 March 2020 - - US-based commercial-stage biopharmaceutical company VBI Vaccines Inc. (NASDAQ: VBIV) has named Damian Braga to its board of directors, the company said.

Braga spent 27 years at Sanofi Pasteur, the human vaccines business of Sanofi Group, retiring in 2015 as the senior vice president, Global Commercial Operations and president, US and the Americas, where he was responsible for leading the development and execution of the commercial strategy for all existing and late-stage products for Sanofi Pasteur's Global Vaccine Business.

Braga brings three decades of vaccine experience from his tenure at Sanofi Pasteur, serving as senior vice president, Global Commercial Operations, from 2010 to 2015, as president, US and the Americas, from 2008 to 2015, and as president, US, from 2002-2007.

During this time, Braga was responsible for growing US vaccine revenues from USD 766m in 2001 to over USD 3.1bn in 2015.

He was also responsible for successfully launching both a high-dose and quadrivalent flu vaccine, generating over USD 1.5bn in global flu vaccine annual revenue.

Prior to assuming responsibility as the most senior company executive in the Americas, Braga held a number of other roles within Sanofi Pasteur, including chief financial officer for the US Business Unit.

Since retirement from Sanofi Pasteur in 2015, Braga founded DAB Consulting Services, a pharmaceutical commercialisation consulting firm, and since 2017, he has served on the advisory board for VaxCare, a company that provides vaccination solutions for physicians, healthcare systems, employers, and school systems.

Braga earned a Bachelor of Economics degree from the University of Miami, and an MBA in Finance from Seton Hall University.

VBI Vaccines is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.

VBI is advancing the prevention and treatment of hepatitis B, with the only trivalent hepatitis B vaccine, Sci-B-Vac, which is approved for use and commercially available in Israel, and recently completed its Phase 3 programme in the US, Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B.

VBI's enveloped virus-like particle platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response.

VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma and a prophylactic CMV vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.